Humanized anti-EGFR monoclonal antibody (Hualan Biological Engineering/Henan shengming biotechnology)

重组抗EGFR全人源单克隆抗体

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHumanized anti-EGFR monoclonal antibody (Hualan Biological Engineering/Henan shengming biotechnology)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHenan Shengming Biotechnology Research Institute Co LtdHualan Ankang Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHenan Shengming Biotechnology Research Institute Co LtdHualan Ankang Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A